TY - JOUR
AU - Todd, George
AB - IntroductionTreatment‐resistant epilepsy (TRE) affects 30% of epilepsy patients and can progressively impair neurological function and quality of life, and cause injury and death from sudden unexpected death in epilepsy (SUDEP), and cause other seizure‐related (e.g. drowning), and indirect (e.g. metabolic disorder from medication side effects) consequences. Among young adult TRE patients, epilepsy kills 3%–6% per decade.1,2 Most TRE patients suffer ongoing seizures despite disabling side effects from multiple anti‐seizure medications (ASMs). There is a dire need for new therapies exploiting novel mechanisms of action.Cannabis (marijuana) species contain more than 500 compounds, including the cannabinoids Δ‐9‐tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is the main psychoactive compound and CBD is the main non‐psychoactive compound in cannabis. Other cannabinoids and non‐cannabinoid molecules in cannabis have diverse biologic activities.3 Artisanal cannabis strains with high‐CBD:THC ratios gained widespread media attention to treat children with TREs such as Dravet Syndrome (DS) and Lennox–Gastaut Syndrome (LGS).4,5 Small unblinded trials used different combinations of CBD, THC, and other cannabinoids, terpenes and flavonoids that rarely documented the precise contents, purity, or consistency of the products. A good manufacturing process (GMP) quality high‐CBD/low‐THC (50:1) formulation had comparable safety and efficacy in an open‐label study to treat seizures in Dravet 
TI - Observational study of medical marijuana as a treatment for treatment‐resistant epilepsies
JF - Annals of Clinical and Translational Neurology
DO - 10.1002/acn3.51537
DA - 2022-04-01
UR - https://www.deepdyve.com/lp/wiley/observational-study-of-medical-marijuana-as-a-treatment-for-treatment-OhJALdVxLA
SP - 497
EP - 505
VL - 9
IS - 4
DP - DeepDyve
ER -